Jude Onyia is CSO at NEUROCRINE BIOSCIENCES INC (NBIX). They have made 2 open-market trades across 1 company since 2022, most recently 2026-09-11.
CIK 0001894425
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NBIX | 22,647 | $3.1M |
Shares reported on the most recent Form 4, priced at the 2026-09-15 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NBIX | SELL · 10b5-1 | 2026-06-01 | 2026-06-02 | $160.25 | $1.8M | +1.6% | +10.9% | -1.9% |
| NBIX | SELL · 10b5-1 | 2026-05-27 | 2026-05-29 | $155.53 | $1.7M | +0.9% | +6.6% | -2.2% |
| NBIX | SELL · 10b5-1 | 2025-07-09 | 2025-07-11 | $130.46 | $15.6M | +1.0% | -6.3% | +4.6% |
| NBIX | SELL · 10b5-1 | 2025-07-02 | 2025-07-07 | $130.13 | $5.3M | +5.0% | +0.5% | +9.1% |
| NBIX | SELL · 10b5-1 | 2025-02-13 | 2025-02-14 | $116.79 | $672K | +2.2% | -3.1% | +4.6% |
| NBIX | SELL · 10b5-1 | 2025-01-31 | 2025-02-04 | $152.97 | $19K | -24.2% | -25.7% | -27.6% |
| NBIX | SELL · 10b5-1 | 2024-11-29 | 2024-12-03 | $126.29 | $589K | +1.0% | +9.9% | -8.8% |
| NBIX | SELL · 10b5-1 | 2024-02-13 | 2024-02-15 | $132.94 | $381K | +0.4% | +3.9% | +5.9% |
| NBIX | SELL · 10b5-1 | 2024-01-31 | 2024-02-02 | $141.94 | $18K | -6.7% | -5.7% | -1.0% |
| NBIX | SELL · 10b5-1 | 2023-11-29 | 2023-12-01 | $113.57 | $529K | +5.7% | +12.7% | +11.5% |
| NBIX | SELL · 10b5-1 | 2023-08-21 | 2023-08-23 | $107.37 | $687K | +2.1% | +5.6% | +1.8% |
| NBIX | SELL | 2023-02-07 | 2023-02-08 | $102.30 | $922K | -2.5% | -8.5% | -7.2% |
| NBIX | SELL · 10b5-1 | 2023-01-31 | 2023-02-02 | $108.48 | $14K | -5.8% | -7.8% | -9.8% |
| NBIX | SELL | 2022-11-29 | 2022-12-01 | $121.90 | $568K | -5.1% | -4.2% | -19.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.